Global demethylation in loss of imprinting subtype of wilms tumor

Genes Chromosomes and Cancer

Volumn 52, Issue 2, 2013, Pages 174-184

  Ludgate, Jackie L ^a   Le Mée, Gwenn ^a   Fukuzawa, Ryuji ^b   Rodger, Euan J ^a   Weeks, Robert J ^a   Reeve, Anthony E ^c   Morison, Ian M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

SATELLITE DNA; SOMATOMEDIN B;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; GENE LOCUS; GENOME IMPRINTING; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM;

BLOTTING, SOUTHERN; DNA METHYLATION; DNA, SATELLITE; GENOMIC IMPRINTING; GENOMIC INSTABILITY; HUMANS; INSULIN-LIKE GROWTH FACTOR II; POLYMERASE CHAIN REACTION; WILMS TUMOR;

EID: 84871060325     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22017     Document Type: Article

References (62)

1. Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber DA, Bernstein BE. 2010. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell 6: 591-602.
2. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J. 1994. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7: 91-97.
3. Beckwith JB. 1998. Nephrogenic rests and the pathogenesis of Wilms tumor: Developmental and clinical considerations. Am J Med Genet 79: 268-273.
4. Beckwith JB, Kiviat NB, Bonadio JF. 1990. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 10: 1-36.
5. Bjornsson HT, Brown LJ, Fallin MD, Rongione MA, Bibikova M, Wickham E, Fan JB, Feinberg AP. 2007. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 99: 1270-1273.
6. Bown N, Cotterill SJ, Roberts P, Griffiths M, Larkins S, Hibbert S, Middleton H, Kelsey A, Tritton D, Mitchell C. 2002. Cytogenetic abnormalities and clinical outcome in Wilms tumor: A study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 38: 11-21.
7. Cadieux B, Ching TT, VandenBerg SR, Costello JF. 2006. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66: 8469-8476.
8. Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N, Reisner Y, Kaminski N, Rechavi G. 2006. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 66: 6040-6049.
9. Dome JS, Coppes MJ. 2002. Recent advances in Wilms tumor genetics. Curr Opin Pediatr 14: 5-11.
10. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. 2000. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
11. Ehrlich M. 2002. DNA methylation in cancer: Too much, but also too little. Oncogene 21: 5400-5413.
12. Ehrlich M. 2006. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 310: 251-274.
13. Ehrlich M, Jiang G, Fiala E, Dome JS, Yu MC, Long TI, Youn B, Sohn OS, Widschwendter M, Tomlinson GE, Chintagumpala M, Champagne M, Parham D, Liang G, Malik K, Laird PW. 2002. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 21: 6694-6702.
14. Ehrlich M, Hopkins NE, Jiang G, Dome JS, Yu MC, Woods CB, Tomlinson GE, Chintagumpala M, Champagne M, Dillerg L, Parham DM, Sawyer J. 2003. Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genet Cytogenet 141: 97-105.
15. Ehrlich M, Woods CB, Yu MC, Dubeau L, Yang F, Campan M, Weisenberger DJ, Long T, Youn B, Fiala ES, Laird PW. 2006. Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 25: 2636-2645.
16. Ehrlich M, Sanchez C, Shao C, Nishiyama R, Kehrl J, Kuick R, Kubota T, Hanash SM. 2008. ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 41: 253-271.
17. Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
18. Fujimoto R, Kinoshita Y, Kawabe A, Kinoshita T, Takashima K, Nordborg M, Nasrallah ME, Shimizu KK, Kudoh H, Kakutani T. 2008. Evolution and control of imprinted FWA genes in the genus Arabidopsis. PLoS Genet 4: e1000048.
19. Fukuzawa R, Breslow NE, Morison IM, Dwyer P, Kusafuka T, Kobayashi Y, Becroft DM, Beckwith JB, Perlman EJ, Reeve AE. 2004. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 363: 446-451.
20. Fukuzawa R, Heathcott RW, Morison IM, Reeve AE. 2005. Imprinting, expression, and localisation of DLK1 in Wilms tumours. J Clin Pathol 58: 145-150.
21. Fukuzawa R, Anaka MR, Heathcott RW, McNoe LA, Morison IM, Perlman EJ, Reeve AE. 2008. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes. J Pathol 215: 377-387.
22. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. 2009. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 28: 1063-1075.
23. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492.
24. Grunau C, Sanchez C, Ehrlich M, van der Bruggen P, Hindermann W, Rodriguez C, Krieger S, Dubeau L, Fiala E, De Sario A. 2005. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 43: 11-24.
25. Hassan KM, Norwood T, Gimelli G, Gartler SM, Hansen RS. 2001. Satellite 2 methylation patterns in normal and ICF syndrome cells and association of hypomethylation with advanced replication. Hum Genet 109: 452-462.
26. Hubertus J, Lacher M, Rottenkolber M, Muller-Hocker J, Berger M, Stehr M, von Schweinitz D, Kappler R. 2011. Altered expression of imprinted genes in Wilms tumors. Oncol Rep 25: 817-823.
27. Jeanpierre M. 1994. Human satellites 2 and 3. Ann Genet 37: 163-171.
28. Jiang YL, Rigolet M, Bourc'his D, Nigon F, Bokesoy I, Fryns JP, Hulten M, Jonveaux P, Maraschio P, Megarbane A, Moncla A, Viegas-Pequignot E. 2005. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum Mutat 25: 56-63.
29. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
30. Lee C, Wevrick R, Fisher RB, Ferguson-Smith MA, Lin CC. 1997. Human centromeric DNAs. Hum Genet 100: 291-304.
31. Lehnertz B, Ueda Y, Derijck AA, Braunschweig U, Perez-Burgos L, Kubicek S, Chen T, Li E, Jenuwein T, Peters AH. 2003. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 13: 1192-1200.
32. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, Tycko B. 2002. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160: 2181-2190.
33. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, D'Agati V, Licht JD, Tycko B. 2004. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165: 1943-1953.
34. Little M, Wells C. 1997. A clinical overview of WT1 gene mutations. Hum Mutat 9: 209-225.
35. Lunn DJ, Thomas A, Best N, Spiegelhalter D. 2000. WinBUGS-A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 10: 325-337.
36. Mummert SK, Lobanenkov VA, Feinberg AP. 2005. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 43: 155-161.
37. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE. 1993. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362: 749-751.
38. Okamoto K, Morison IM, Taniguchi T, Reeve AE. 1997. Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci USA 94: 5367-5371.
39. Oliver VF, Miles HL, Cutfield WS, Hofman PL, Ludgate JL, Morison IM. 2012. Defects in imprinting and genome-wide DNA methylation are not common in the in vitro fertilization population. Fertil Steril 97: 147-153e147.
40. Pode-Shakked N, Dekel B. 2011. Wilms tumor-A renal stem cell malignancy? Pediatr Nephrol 26: 1535-1543.
41. Pritchard-Jones K, Vujanic GM. 2010. Recent Developments in the Molecular Pathology of Paediatric Renal Tumours. Open Pathol J 4: 32-39.
42. Qu G, Dubeau L, Narayan A, Yu MC, Ehrlich M. 1999a. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 423: 91-101.
43. Qu GZ, Grundy PE, Narayan A, Ehrlich M. 1999b. Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet 109: 34-39.
44. Rassekh SR, Chan S, Harvard C, Dix D, Qiao Y, Rajcan-Separovic E. 2008. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays. Cancer Genet Cytogenet 182: 84-94.
45. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP. 2001. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 93: 1698-1703.
46. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. 2007. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315: 642-645.
47. Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J, Bestor TH. 2006. Large-scale structure of genomic methylation patterns. Genome Res 16: 157-163.
48. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A, Torres A. 2005. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213-7223.
49. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. 2001. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33: 561-568.
50. Spiegelhalter DJ, Best NG, Carlin BR, van der Linde A. 2002. Bayesian measures of model complexity and fit. J Roy Stat Soc B 64: 583-616.
51. Steenman M, Redeker B, de Meulemeester M, Wiesmeijer K, Voute PA, Westerveld A, Slater R, Mannens M. 1997. Comparative genomic hybridization analysis of Wilms tumors. Cytogenet Cell Genet 77: 296-303.
52. Warburton PE, Hasson D, Guillem F, Lescale C, Jin X, Abrusan G. 2008. Analysis of the largest tandemly repeated DNA families in the human genome. BMC Genomics 9: 533.
53. Watanabe N, Nakadate H, Haruta M, Sugawara W, Sasaki F, Tsunematsu Y, Kikuta A, Fukuzawa M, Okita H, Hata J, Soejima H, Kaneko Y. 2006. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 45: 592-601.
54. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schubeler D. 2005. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 853-862.
55. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW. 2005. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33: 6823-6836.
56. Widschwendter M, Jiang G, Woods C, Muller HM, Fiegl H, Goebel G, Marth C, Muller-Holzner E, Zeimet AG, Laird PW, Ehrlich M. 2004. DNA hypomethylation and ovarian cancer biology. Cancer Res 64: 4472-4480.
57. Willard HF, Waye JS. 1987. Chromosome-specific subsets of human alpha satellite DNA: Analysis of sequence divergence within and between chromosomal subsets and evidence for an ancestral pentameric repeat. J Mol Evol 25: 207-214.
58. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 16: 2036-2045.
59. Wilson AS, Power BE, Molloy PL. 2007. DNA hypomethylation and human diseases. Biochim Biophys Acta 1775: 138-162.
60. Xiong Z, Laird PW. 1997. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534.
61. Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B. 2005. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 3: 493-502.
62. Zagradisnik B, Kokalj-Vokac N. 2000. Hypomethylation of alphoid DNA and classical satellite DNA on chromosome 1, 9, 16 and Y in extraembryonic tissue. Pflugers Arch 440: R190-192.